GT216 / Grit Biotechnology - LARVOL DELTA

A genetically modified tumor-infiltrating lymphocytes product (GT216) enhanced anti-tumor efficacy against solid tumor by fine-tuning multiple negative immune regulators (AACR 2024) - "Notably, GT216 TILs eradicated tumor growth with low IL-2 support in NOG mice inoculated with HLA-matched tumor cells while conventional TILs showed limited tumor control with high IL-2, corelated with their better infiltration and persistence in tumor and periphery. In summary, GT216 demonstrated enhanced anti-tumor efficacy and persistence as well as reduced IL-2 dependency in vitro and in vivo, supporting the clinical evaluation of GT216 as a next-generation TIL therapy in treatment of refractory solid tumors."

Clinical • Tumor-infiltrating lymphocyte • Oncology • Solid Tumor • IL2